Late-onset thymidine kinase 2 deficiency: a review of 18 cases.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
06 05 2019
Historique:
received: 05 02 2019
accepted: 17 04 2019
entrez: 8 5 2019
pubmed: 8 5 2019
medline: 26 11 2019
Statut: epublish

Résumé

TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity. We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence of clinical symptoms until the age of 12. The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance, where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed multiple mtDNA deletions but mtDNA depletion was present only in two patients. The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.

Sections du résumé

BACKGROUND
TK2 gene encodes for mitochondrial thymidine kinase, which phosphorylates the pyrimidine nucleosides thymidine and deoxycytidine. Recessive mutations in the TK2 gene are responsible for the 'myopathic form' of the mitochondrial depletion/multiple deletions syndrome, with a wide spectrum of severity.
METHODS
We describe 18 patients with mitochondrial myopathy due to mutations in the TK2 gene with absence of clinical symptoms until the age of 12.
RESULTS
The mean age of onset was 31 years. The first symptom was muscle limb weakness in 10/18, eyelid ptosis in 6/18, and respiratory insufficiency in 2/18. All patients developed variable muscle weakness during the evolution of the disease. Half of patients presented difficulty in swallowing. All patients showed evidence of respiratory muscle weakness, with need for non-invasive Mechanical Ventilation in 12/18. Four patients had deceased, all of them due to respiratory insufficiency. We identified common radiological features in muscle magnetic resonance, where the most severely affected muscles were the gluteus maximus, semitendinosus and sartorius. On muscle biopsies typical signs of mitochondrial dysfunction were associated with dystrophic changes. All mutations identified were previously reported, being the most frequent the in-frame deletion p.Lys202del. All cases showed multiple mtDNA deletions but mtDNA depletion was present only in two patients.
CONCLUSIONS
The late-onset is the less frequent form of presentation of the TK2 deficiency and its natural history is not well known. Patients with late onset TK2 deficiency have a consistent and recognizable clinical phenotype and a poor prognosis, due to the high risk of early and progressive respiratory insufficiency.

Identifiants

pubmed: 31060578
doi: 10.1186/s13023-019-1071-z
pii: 10.1186/s13023-019-1071-z
pmc: PMC6501326
doi:

Substances chimiques

DNA, Mitochondrial 0
thymidine kinase 2 EC 2.7.1.-
Thymidine Kinase EC 2.7.1.21

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100

Subventions

Organisme : NINDS NIH HHS
ID : U54 NS078059
Pays : United States
Organisme : NICHD NIH HHS
ID : P01 HD080642
Pays : United States

Références

PLoS One. 2016 Feb 11;11(2):e0148709
pubmed: 26867126
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1539-1555
pubmed: 28215579
J Med Genet. 2018 Aug;55(8):515-521
pubmed: 29602790
Med Clin (Barc). 2000 Feb 5;114(4):121-7
pubmed: 10734620
Neuromuscul Disord. 2018 Oct;28(10):828-836
pubmed: 30166250
Neurology. 2008 Sep 2;71(10):758-65
pubmed: 18765652
J Int Med Res. 2018 Mar;46(3):1153-1161
pubmed: 29210305
Med Sci Sports Exerc. 2011 Aug;43(8):1465-73
pubmed: 21228724
Nat Genet. 2001 Nov;29(3):342-4
pubmed: 11687801
Essays Biochem. 2018 Jul 20;62(3):467-481
pubmed: 29980632
Mol Genet Metab. 2018 Jun;124(2):124-130
pubmed: 29735374
Pediatr Res. 2010 Aug;68(2):151-4
pubmed: 20421844
Brain. 2003 Feb;126(Pt 2):413-23
pubmed: 12538407
J Inherit Metab Dis. 2017 Jul;40(4):587-599
pubmed: 28324239
Neuromuscul Disord. 2018 May;28(5):408-413
pubmed: 29567350
Hum Mol Genet. 2012 Jan 1;21(1):66-75
pubmed: 21937588
Ann Neurol. 2017 May;81(5):641-652
pubmed: 28318037
Neurology. 2015 Jun 2;84(22):2286-8
pubmed: 25948719
Neuromuscul Disord. 2011 Aug;21(8):533-42
pubmed: 21676617
Med Sci Sports Exerc. 2018 Jun;50(6):1142-1151
pubmed: 29315169
Ann Neurol. 2015 Nov;78(5):814-23
pubmed: 26463265
Mitochondrion. 2009 Jul;9(4):242-6
pubmed: 19272467
J Neurol. 2015 Mar;262(3):701-10
pubmed: 25559684
BMC Genomics. 2014 Feb 01;15:91
pubmed: 24484525
Eur Radiol. 2018 Dec;28(12):5293-5303
pubmed: 29802573
Mol Genet Metab. 2013 Sep-Oct;110(1-2):35-41
pubmed: 23911206
Neurology. 2013 Dec 3;81(23):2051-3
pubmed: 24198295
Neurotherapeutics. 2013 Apr;10(2):186-98
pubmed: 23385875
Hum Mol Genet. 2014 May 1;23(9):2459-67
pubmed: 24362886

Auteurs

Cristina Domínguez-González (C)

Neurology department, Neuromuscular disorders Unit, 12 de Octubre Hospital, Madrid, Spain.
Research Institute i+12, 12 de Octubre Hospital, Madrid, Spain.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Aurelio Hernández-Laín (A)

Neuropathology, Pathology Department, Neuromuscular disorders Unit, 12 de Octubre Hospital, Madrid, Spain.

Eloy Rivas (E)

Pathological Anatomic Department, Neuromuscular Disorders Unit, Instituto de Biomedicina de Sevilla, Hospital U. Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, Spain.

Ana Hernández-Voth (A)

Neumology department, Neuromuscular disorders Unit, 12 de Octubre Hospital, Madrid, Spain.

Javier Sayas Catalán (J)

Neumology department, Neuromuscular disorders Unit, 12 de Octubre Hospital, Madrid, Spain.

Roberto Fernández-Torrón (R)

Neurology Department, Neuromuscular disorders Unit, Hospital de Donostia, San Sebastian, Spain.

Carmen Fuiza-Luces (C)

Research Institute i+12, 12 de Octubre Hospital, Madrid, Spain.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital '12 de Octubre' ('i+12'), Madrid, Spain.

Jorge García García (J)

Neurology Department, Hospital de Albacete, Albacete, Spain.

Germán Morís (G)

Neurology Department, Neuromuscular disorders Unit, Hospital Central de Asturias, Oviedo, Spain.

Montse Olivé (M)

Pathological Anatomy Department, Neuromuscular disorders unit, IDIBELL-Hospital de Bellvitge, Barcelona, Spain.

Frances Miralles (F)

Neurology department, Neuromuscular disorders unit, Hospital Universitari Son Espases, Palma, Spain.

Jordi Díaz-Manera (J)

Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Neurology department, Neuromuscular disorders unit, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.

Candela Caballero (C)

Respiratory Department, Instituto de Biomedicina de Sevilla, Hospital U. Virgen del Rocío, CSIC, CIBERES, Universidad de Sevilla, Sevilla, Spain.

Bosco Méndez-Ferrer (B)

Rehabilitation Department, Hospital Virgen del Rocio, Sevilla, Spain.

Ramon Martí (R)

Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Neuromuscular Unit, Neurology Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain.

Elena García Arumi (E)

Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Research group on Neuromuscular and Mitochondrial Diseases, Valld'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.

María Carmen Badosa (MC)

Neuromuscular Unit, Neurology Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain.

Jesús Esteban (J)

Neurology department, Neuromuscular disorders Unit, 12 de Octubre Hospital, Madrid, Spain.
Research Institute i+12, 12 de Octubre Hospital, Madrid, Spain.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Cecilia Jimenez-Mallebrera (C)

Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Neuromuscular Unit, Neurology Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain.

Alberto Blazquez Encinar (AB)

Research Institute i+12, 12 de Octubre Hospital, Madrid, Spain.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital '12 de Octubre' ('i+12'), Madrid, Spain.

Joaquín Arenas (J)

Research Institute i+12, 12 de Octubre Hospital, Madrid, Spain.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital '12 de Octubre' ('i+12'), Madrid, Spain.

Michio Hirano (M)

Department of Neurology, H. Houston Merritt Center, Columbia University Medical Center, New York, New York, USA.

Miguel Ángel Martin (MÁ)

Research Institute i+12, 12 de Octubre Hospital, Madrid, Spain.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Mitochondrial and Neuromuscular Diseases Laboratory, Research Institute of Hospital '12 de Octubre' ('i+12'), Madrid, Spain.

Carmen Paradas (C)

Neurology Department, Neuromuscular Disorders Unit, Instituto de Biomedicina de Sevilla, Hospital U. Virgen del Rocío, CSIC, Universidad de Sevilla, Avd. Manuel Siurot s/n, 41013, Sevilla, Spain. cparadas@us.es.
Biomedical Network Research Centre on Neurodegenerative Diseases (CIBERNED), Madrid, Spain. cparadas@us.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH